An Integrated Model for Determining Causes of Poor Oral Drug Absorption

AbstractPurpose. To develop an integrated absorption model for estimating the fraction of dose absorbed and determining the causes of poor oral drug absorption. Methods. Both analytical and numerical methods were used to estimate the fraction of dose absorbed. Results. An integrated absorption model was developed by considering transit flow, dissolution, and permeation processes, simultaneously. A framework was proposed to determine permeability-, dissolution-, and solubility-limited absorption. Digoxin, griseofulvin, and panadiplon were employed to illustrate the applications of the integrated model in identifying the causes of poor absorption and guiding formulation development. Conclusions. The integrated absorption model was successfully applied to digoxin, griseofulvin, and panadiplon to estimate the fraction dose absorbed and to roughly determine the causes of poor oral drug absorption.

[1]  R. J. Hintz,et al.  The effect of particle size distribution on dissolution rate and oral absorption , 1989 .

[2]  J. Dressman,et al.  Mixing-tank model for predicting dissolution rate control or oral absorption. , 1986, Journal of pharmaceutical sciences.

[3]  G L Amidon,et al.  Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. , 1996, Advanced drug delivery reviews.

[4]  Lawrence X. Yu,et al.  Characterization of small intestinal transit time distribution in humans , 1998 .

[5]  M. Mayersohn.  Principles of drug absorption , 2002 .

[6]  D. Azarnoff,et al.  Absorption of orally given digoxin preparations. , 1972, JAMA.

[7]  S. Riegelman,et al.  Absorption characteristics of solid dispersed and micronized griseofulvin in man. , 1971, Journal of pharmaceutical sciences.

[8]  J. O'grady,et al.  The influence of digoxin particle size on absorption of digoxin and the effect of propantheline and metoclopramide. , 1978, British journal of clinical pharmacology.

[9]  E. Townley,et al.  Parameters affecting absorption of griseofulvin in a human subject using urinary metabolite excretion data. , 1970, Journal of pharmaceutical sciences.

[10]  P. Pentikäinen,et al.  Effect of particle size on the bioavailability of digoxin , 1975, European Journal of Clinical Pharmacology.

[11]  G L Amidon,et al.  Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[12]  A. Marzo,et al.  Bioavailability and related heart function index of digoxin capsules and tablets in cardiac patients. , 1979, Journal of pharmaceutical sciences.

[13]  T. Gramatté.  Griseofulvin absorption from different sites in the human small intestine , 1994, Biopharmaceutics & drug disposition.

[14]  J. E. Carless,et al.  The effect of particle size on the absorption of digoxin , 1974, European Journal of Clinical Pharmacology.

[15]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[16]  V. Manninen,et al.  Altered absorption of digoxin in patients given propantheline and metoclopramide. , 1973, Lancet.